Johnson & Johnson and Nippon Shinyaku Gain Japan Approval for Opsumit in Pediatric Pulmonary Arterial Hypertension
I'm PortAI, I can summarize articles.
Johnson & Johnson and Nippon Shinyaku have received approval from Japan's Ministry of Health for Opsumit® tablets for pediatric pulmonary arterial hypertension. The approval includes 10 mg tablets and pediatric dispersible tablets in 1.0 mg and 2.5 mg doses for patients aged three months and older. This decision was based on global and local clinical studies, and the product will be jointly promoted in Japan by both companies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments